TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02597049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Administered orally as standard of care for type 2 diabetes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Administered orally as standard of care for type 2 diabetes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Administered orally as standard of care for type 2 diabetes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally as standard of care for type 2 diabetes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered orally as standard of care for type 2 diabetes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Administered orally as standard of care for type 2 diabetes
Study: NCT04733508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 111In-DTPA-exendin-4
Description: Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRDye800CW-exendin-4
Description: Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy
Study: NCT03844230

Intervention type: OTHER
Group type: OTHER
Intervention: Control - Inhibition
Description: Taste and spit up water 10 minutes before drinking a glucose load

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental I- Inhibition
Description: Taste and spit up water 10 minutes before drinking a glucose load mixed with lactisole

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental II- Inhibition
Description: Taste and spit up sucralose 10 minutes before drinking a glucose load mixed with lactisole

Intervention type: OTHER
Group type: OTHER
Intervention: Control- Stimulation
Description: Taste and spit up water 10 minutes before drinking a glucose load

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental I- Stimulation
Description: Taste and spit up sucralose 10 minutes before drinking a glucose load
Study: NCT04013854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab
Description: All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nivolumab
Description: All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: All arms will receive a pre-surgery dose of nivolumab (480 mg IV). Post-surgery nivolumab doses will be determined by pathologic response and randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Only subjects who fail to achieve a complete, or near complete, pathological response, and are then randomized to Arm C will receive Ipilimumab (1 mg/kg) )
Study: NCT02520362

Intervention type: DRUG
Intervention: denosumab
Description: subcutaneous injection

Intervention type: DRUG
Intervention: denosumab
Description: subcutaneous injection

Intervention type: DRUG
Intervention: denosumab
Description: subcutaneous injection

Intervention type: DRUG
Intervention: bisphosphonate
Description: The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate \[Fosamax®\], risedronate \[Actonel®\], ibandronate \[Boniva®/Bonviva®\] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate \[Reclast®/Aclasta®\].
Study: NCT06639152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oil-based contrast medium
Description: In oil group, ethiodized poppyseed oil (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 480 mg/ml) was used as the contrast medium for hysterosalpingography.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: water-based contrast medium
Description: In water group, Ioversol (Jiangsu Hengrui Medicine Co., Ltd., Lianyungang, Jiangsu Province, China, H20067895, iodine concentration of 320 mg/ml) was used as the contrast medium for hysterosalpingography.
Study: NCT03844230

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental II- Stimulation
Description: Drink sucralose 10 minutes before drinking a glucose load

Intervention type: OTHER
Group type: OTHER
Intervention: Sensory Evaluation
Description: Taste different solutions to evaluate sweet taste preference, suprathreshold intensity and detection threshold

Intervention type: OTHER
Group type: OTHER
Intervention: Sensory Evaluation
Description: Taste different solutions to evaluate sweet taste preference, suprathreshold intensity and detection threshold
Study: NCT01499160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Drug is are to be taken orally. 2.5 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Drug is to be taken orally. 5 mg once daily.
Study: NCT04659486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Description: Online strength and aerobic home-based exercise training, 3 times per week, for 12 weeks. The exercise program is composed by 2 intensity-levels (starter and advanced).
Study: NCT04175860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The intervention with the patient (Chronic Patient Care Group and his family.)
Description: * Characterization: through the application of the characterization survey of the dyad (patient-caregiver),~* Evaluation of the competence to care at home: Application of the instrument 'competence to care at home, long and short version both the patient and the family caregiver.~* Risk assessment: this step is made based on the complexity of the treatment and the results of the evaluation the competence to care at home.
Study: NCT00831987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®: Influenza virus vaccine 2004-2005 formulation
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®: Influenza virus vaccine 2004-2005 formulation
Description: 0.5 mL, Intramuscular
Study: NCT01407484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
Study: NCT04385043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasma hyperimmune
Description: patients will receive this as add on therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: patients will receive only standard therapy for Covid-19 infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: patients will receive only standard therapy for Covid-19 infection
Study: NCT01478516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravitreal injection
Description: autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
Study: NCT03525249

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutraceutical
Description: Subjects will consume a capsule for eight weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutraceutical
Description: Subjects will consume a capsule for eight weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nutraceutical
Description: Subjects will consume a capsule for eight weeks
Study: NCT01566994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TTM Tailored
Description: This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy
Description: This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Treatment
Description: This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
Study: NCT04427670

Intervention type: OTHER
Group type: OTHER
Intervention: Group intervention
Description: Group intervention programme designed for stroke survivors with dysarthria and their carers. The programme was eight weeks long, with weekly two sessions, each session lasting for two hours, lead by speech language therapist and was comprised of activities which addressed participants education about their dysarthria and stroke. The role of family , peer and professional was to provide support and communication practice.

Intervention type: OTHER
Group type: OTHER
Intervention: Regular speech therapy
Description: Regular speech therapy will be provided to the controlled group.Regular speech therapy is one to one speech therapy session,conducted twice a week for the duration of eight weeks.This intervention is implemented to patients with dysarthria following stroke in a format of one patient and one therapist per session.
Study: NCT01298973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: One group will receive Saline to irrigate the wound
Study: NCT01327456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Intervention
Description: patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
Study: NCT04554173

Intervention type: PROCEDURE
Intervention: surgical resection neurogenic tumors
Description: Patient who was treated for a thoracic neurogenic tumor by minimally invasive surgery
Study: NCT00117195

Intervention type: DEVICE
Intervention: Automated Neuropsychological Assessment Matrix
Description: This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions.~In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome.
Study: NCT04091750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Induction: 3mg/kg IV every 3 weeks x 4 cycles~Maintenance: 480mg IV every 4 weeks for up to 92 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction: 1mg/kg IV every 3 weeks x 4 cycles
Study: NCT03917212

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, observational study with metabolic characterisation
Study: NCT04091750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Induction and Maintenance: 40mg PO daily
Study: NCT00202176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide
Description: Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
Study: NCT00202176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium Bromide
Description: Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
Study: NCT04008238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: - Trabectedin will be prescribed as per market authorization and will be administered by intraveinous infusion (1,5 mg/m²) every 3 weeks. A treatment cycle is defined as a 3-weeks period
Study: NCT00739050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 20mg daily at nights for 12 weeks. Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: placebo daily at nights for 12 weeks. Tablets
Study: NCT00482261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: 100mg/day
Study: NCT02883647

Intervention type: DRUG
Intervention: Entecavir or Tenofovir
Description: Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again
Study: NCT03392324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRIMA
Description: Implantation of PRIMA device
Study: NCT02453529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 4873
Description: Oral tablets
Study: NCT03587194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otezla
Description: Otezla 30mg BID
Study: NCT01827228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assays
Description: May vary across sites
Study: NCT05712369

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~* 50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~* 8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~* 50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~* 8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Before the anti-CD20 monoclonal antibodies treatment (e.g. Rituximab/Ofatumumab) and after 6, 9 and 12, 24 months from the first infusion the following blood samples will be collected for the analysis of lymphocyte subpopulations:~* 50/100 mL of blood (20 mL for pediatric patients) for Peripheral Blood Mononuclear Cells (PBMCs) isolation.~* 8 mL of blood (both adult and pediatric) to obtain serum. Serum will be obtained by standard centrifugation and PBMC will be isolated by Ficoll-Paque® density gradient centrifugation, according to manufacturer's instruction.
Study: NCT04548648

Intervention type: DRUG
Group type: OTHER
Intervention: Acalabrutinib
Description: Acalabrutinib at 100 mg is taken orally approximately every 12 hours until disease progression or unacceptable toxicity.
Study: NCT04015622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg PO OD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide 160 mg PO OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV every 3 weeks
Study: NCT03273075

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
Study: NCT03273075

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prasugrel
Description: The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
Study: NCT05931718

Intervention type: BIOLOGICAL
Intervention: cytokine essays
Description: evaluation of immunomodulatory cytokines by ELISA kits on peripheral blood samples

Intervention type: BIOLOGICAL
Intervention: cytokine essays
Description: evaluation of immunomodulatory cytokines by ELISA kits on peripheral blood samples

Intervention type: BIOLOGICAL
Intervention: cytokine essays
Description: evaluation of immunomodulatory cytokines by ELISA kits on peripheral blood samples

Intervention type: BIOLOGICAL
Intervention: cytokine essays
Description: evaluation of immunomodulatory cytokines by ELISA kits on peripheral blood samples

Intervention type: BIOLOGICAL
Intervention: NGS
Description: evaluation of somatic mutations commonly associated with myeloid neoplasm and immunodeficiencies by next generation sequencing on peripheral blood samples

Intervention type: BIOLOGICAL
Intervention: NGS
Description: evaluation of somatic mutations commonly associated with myeloid neoplasm and immunodeficiencies by next generation sequencing on peripheral blood samples

Intervention type: BIOLOGICAL
Intervention: NGS
Description: evaluation of somatic mutations commonly associated with myeloid neoplasm and immunodeficiencies by next generation sequencing on peripheral blood samples

Intervention type: BIOLOGICAL
Intervention: NGS
Description: evaluation of somatic mutations commonly associated with myeloid neoplasm and immunodeficiencies by next generation sequencing on peripheral blood samples

Intervention type: BIOLOGICAL
Intervention: Fecal microbiome
Description: evaluation of fecal microbiome on fecal samples

Intervention type: BIOLOGICAL
Intervention: Fecal microbiome
Description: evaluation of fecal microbiome on fecal samples

Intervention type: BIOLOGICAL
Intervention: Fecal microbiome
Description: evaluation of fecal microbiome on fecal samples

Intervention type: BIOLOGICAL
Intervention: Fecal microbiome
Description: evaluation of fecal microbiome on fecal samples

Intervention type: DRUG
Intervention: Erythropoietin
Description: evaluation of recombinant erythropoietin use, safety and efficacy in patients with autoimmune hemolytic anemia according to clinical practice
Study: NCT01827228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assays
Description: May vary across sites
Study: NCT05931718

Intervention type: DRUG
Intervention: Luspatercept
Description: evaluation of cytokine levels, molecular profile and bone marrow microenvironment by single cell analysis in patients treated with luspatercept according to clinical practice

Intervention type: DRUG
Intervention: Thrombopoietin Receptor Agonist
Description: evaluation of TPO-RA use, safety and efficacy in patients with ITP according to clinical practice

Intervention type: DRUG
Intervention: G-CSF
Description: evaluation of G-CSF use, safety and efficacy in patients with CIN/AIN according to clinical practice
Study: NCT03981055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Comparator: Active tDCS and Active TUS
Description: Device: Transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Sham TDCS and Sham TUS
Description: Device: SHAM Comparator Device: transcranial Direct Current Stimulation (tDCS) Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.~Device: Transcranial Ultrasound (TUS) Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.